<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02638597</url>
  </required_header>
  <id_info>
    <org_study_id>STU 072014-088</org_study_id>
    <nct_id>NCT02638597</nct_id>
  </id_info>
  <brief_title>Gemfibrozil for Nicotine Smoking Cessation</brief_title>
  <acronym>GEMNIC</acronym>
  <official_title>Gemfibrozil for Nicotine Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will test whether gemfibrozil, a well-studied medication for high cholesterol,
      will help people stop smoking nicotine cigarette smoking. The study will also test whether
      gemfibrozil decrease cravings for cigarette and the desire to smoke.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot clinical trial examining the feasibility and efficacy of gemfibrozil
      treatment for smoking cessation. Adults with a desire to quit nicotine cigarette smoking will
      be recruited. Eligible participants will be randomly divided into two groups: those who
      receive gemfibrozil and waitlist controls. Screening will be conducted with a brief phone
      screen followed by a longer screening visit for those who qualify. During the screening
      visit, all study participants will provide demographic information and will be interviewed
      regarding smoking history. Procedures performed during the screening visit include a blood
      draw, urine pregnancy test, physical exam, clinical psychiatric interview, and measurement of
      exhaled carbon monoxide (CO). At baseline, participants will complete the Heavy Smoking Index
      (HSI) and the Brief Questionnaire of Smoking Urges (QSU-Brief). Participants will also
      complete the Quick Inventory of Depressive Symptoms-Self Rated (QIDS-SR) to assess symptoms
      of depression and changes in mood associated with smoking cessation will be assessed with the
      Concise Associated Symptoms Tracking (CAST) scale . Participants will work with the research
      clinician to set a target quit date within one week of the baseline session, and all
      participants will be provided written materials with guidance for smoking cessation as part
      of a smoking cessation counseling session. All participants will attend visits at the
      research clinic at 3 days and 4 weeks from target quit date to assess safety, adherence, and
      smoking status; participants will also receive additional smoking cessation counseling.
      Smoking status will be determined with exhaled breath CO and a single item questionnaire
      regarding the number of cigarettes smoked since target quit date and symptoms of depression
      and mood changes will again be measured. Medication side effects will be quantified using the
      Frequency, Intensity, and Burden of Side Effects Rating (FIBSER) scale. The final study visit
      will occur at 8 weeks after target quit date for completion of the HSI, QIDS-SR, CAST,
      FIBSER, exhaled breath CO, QSU-Brief, and smoking self-report.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">December 23, 2016</completion_date>
  <primary_completion_date type="Actual">December 23, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exhaled Carbon Monoxide (CO)</measure>
    <time_frame>8 weeks after target quit date</time_frame>
    <description>Exhaled carbon monoxide change from baseline to last available visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heaviness of Smoking Index</measure>
    <time_frame>8 weeks after target quit date</time_frame>
    <description>The outcome measure was Heaviness of Smoking Index at exit. The Heaviness of Smoking Index is a two-item scale, with scores on each item rated on a 1-4 likert scale. The total score of the measure ranges from 2-8, with higher scores indicating worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Gemfibrozil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will receive smoking cessation counseling and will be provided gemfibrozil 600 mg twice daily by mouth for 9 weeks, starting one week prior to target quit date and ending with study completion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Waitlist</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants in this arm will receive the smoking cessation counseling but will not receive medication. After completing the trial without medication, participants who continue to smoke and have a desire to quit may choose to enter the gemfibrozil arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemfibrozil</intervention_name>
    <description>FDA Approved Drug(s)/Biologic(s) (study use is not an FDA-approved use)</description>
    <arm_group_label>Gemfibrozil</arm_group_label>
    <other_name>Lopid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>smoking cessation counseling</intervention_name>
    <description>smoking cessation counseling</description>
    <arm_group_label>Gemfibrozil</arm_group_label>
    <arm_group_label>Waitlist</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-64 years

          -  Meet DSM-5 criteria for tobacco use disorder based on cigarette use

          -  Desire to quit smoking

          -  Able to complete assessments and interview in English

        Exclusion Criteria:

          -  Psychiatric co-morbidity posing safety risk, including current suicidality or
             psychosis as assessed on clinical interview

          -  Concurrent use of a statin medication (HMG-CoA reductase inhibitor),anticoagulant, or
             repaglinide

          -  Concurrent use of any FDA-approved medication for smoking cessation

          -  Use of any form of tobacco or nicotine (including vaporizer) other than cigarette
             smoking

          -  Any DSM-5 substance use disorder other than nicotine use disorder

          -  History of intolerance to any fibrate medication

          -  History of gallbladder disease and cholestectomy has not been performed

          -  Baseline liver function tests &gt; twice the upper limit of normal

          -  Severe impairment of renal function (baseline serum creatinine â‰¥ 2 mg/dL)

          -  Currently pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madhukar Trivedi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parkland Memorial Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R, Thase ME, Kocsis JH, Keller MB. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003 Sep 1;54(5):573-83. Erratum in: Biol Psychiatry. 2003 Sep 1;54(5):585.</citation>
    <PMID>12946886</PMID>
  </reference>
  <reference>
    <citation>Trivedi MH, Wisniewski SR, Morris DW, Fava M, Kurian BT, Gollan JK, Nierenberg AA, Warden D, Gaynes BN, Luther JF, Rush AJ. Concise Associated Symptoms Tracking scale: a brief self-report and clinician rating of symptoms associated with suicidality. J Clin Psychiatry. 2011 Jun;72(6):765-74. doi: 10.4088/JCP.11m06840.</citation>
    <PMID>21733477</PMID>
  </reference>
  <reference>
    <citation>Wisniewski SR, Rush AJ, Balasubramani GK, Trivedi MH, Nierenberg AA; STARD Investigators. Self-rated global measure of the frequency, intensity, and burden of side effects. J Psychiatr Pract. 2006 Mar;12(2):71-9.</citation>
    <PMID>16728903</PMID>
  </reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>December 18, 2015</study_first_submitted>
  <study_first_submitted_qc>December 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2015</study_first_posted>
  <results_first_submitted>November 30, 2018</results_first_submitted>
  <results_first_submitted_qc>January 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 1, 2019</results_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Madhukar H. Trivedi, MD</investigator_full_name>
    <investigator_title>Madhukar H. Trivedi, MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemfibrozil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Waitlist</title>
          <description>Participants placed on waitlist for medication, otherwise completed study procedures</description>
        </group>
        <group group_id="P2">
          <title>Gemfibrozil</title>
          <description>Received gemfibrozil tablets</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Waitlist</title>
          <description>Participants placed on waitlist for medication, otherwise completed study procedures</description>
        </group>
        <group group_id="B2">
          <title>Gemfibrozil</title>
          <description>Received gemfibrozil tablets</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.25" spread="14.12"/>
                    <measurement group_id="B2" value="37.50" spread="22.02"/>
                    <measurement group_id="B3" value="31.38" spread="18.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Exhaled Carbon Monoxide (CO)</title>
        <description>Exhaled carbon monoxide change from baseline to last available visit.</description>
        <time_frame>8 weeks after target quit date</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Gemfibrozil</title>
            <description>Participants in this arm will receive smoking cessation counseling and will be provided gemfibrozil 600 mg twice daily by mouth for 9 weeks, starting one week prior to target quit date and ending with study completion
Gemfibrozil: FDA Approved Drug(s)/Biologic(s) (study use is not an FDA-approved use)
smoking cessation counseling: smoking cessation counseling</description>
          </group>
          <group group_id="O2">
            <title>Waitlist</title>
            <description>Participants in this arm will receive the smoking cessation counseling but will not receive medication. After completing the trial without medication, participants who continue to smoke and have a desire to quit may choose to enter the gemfibrozil arm.
smoking cessation counseling: smoking cessation counseling</description>
          </group>
        </group_list>
        <measure>
          <title>Exhaled Carbon Monoxide (CO)</title>
          <description>Exhaled carbon monoxide change from baseline to last available visit.</description>
          <units>Parts p/million</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.88" spread="12.63"/>
                    <measurement group_id="O2" value="21.63" spread="22.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heaviness of Smoking Index</title>
        <description>The outcome measure was Heaviness of Smoking Index at exit. The Heaviness of Smoking Index is a two-item scale, with scores on each item rated on a 1-4 likert scale. The total score of the measure ranges from 2-8, with higher scores indicating worse outcome.</description>
        <time_frame>8 weeks after target quit date</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Waitlist</title>
            <description>Participants placed on waitlist for medication, otherwise completed study procedures</description>
          </group>
          <group group_id="O2">
            <title>Gemfibrozil</title>
            <description>Received gemfibrozil tablets</description>
          </group>
        </group_list>
        <measure>
          <title>Heaviness of Smoking Index</title>
          <description>The outcome measure was Heaviness of Smoking Index at exit. The Heaviness of Smoking Index is a two-item scale, with scores on each item rated on a 1-4 likert scale. The total score of the measure ranges from 2-8, with higher scores indicating worse outcome.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="1.04"/>
                    <measurement group_id="O2" value="1.63" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Gemfibrozil</title>
          <description>Participants in this arm will receive smoking cessation counseling and will be provided gemfibrozil 600 mg twice daily by mouth for 9 weeks, starting one week prior to target quit date and ending with study completion
Gemfibrozil: FDA Approved Drug(s)/Biologic(s) (study use is not an FDA-approved use)
smoking cessation counseling: smoking cessation counseling</description>
        </group>
        <group group_id="E2">
          <title>Waitlist</title>
          <description>Participants in this arm will receive the smoking cessation counseling but will not receive medication. After completing the trial without medication, participants who continue to smoke and have a desire to quit may choose to enter the gemfibrozil arm.
smoking cessation counseling: smoking cessation counseling</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Ended up being gallbladder disease.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arm bruising</sub_title>
                <description>Arm bruising as a result of study-related blood draw.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Principal Investigator</name_or_title>
      <organization>University of Texas Southwestern Medical Center</organization>
      <phone>2146480188</phone>
      <email>madhukar.trivedi@UTSouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

